Details of the Drug

General Information of Drug (ID: DMHP21E)

• Drug Name: Hydromorphone
• Synonyms: hydromorphone; Dihydromorphinone; Dimorphone; Idromorfone; Hydromorphon; Dihydromorfinon; Hydromorfona; Laudacon; DiMo; Hydromorphonum; 7,8-Dihydromorphinone; Novolaudon; Hidromorfona; Dilaudid; Dilaudid Oros; Hydromorfona [Spanish]; Dihydromorfinon [Czech]; 466-99-9; Hydromorphonum [INN-Latin]; Hidromorfona [INN-Spanish]; Palladone; 6-Deoxy-7,8-dihydro-6-oxomorphine; Morphinone, dihydro-; Idromorfone [DCIT]; Laudicon; Hydromorphone [INN:BAN]; Dilaudid-hp; 4,5-Epoxy-3-hydroxy-17-methylmorphinan-6-one; DiMo; Hydromorphone HCL; Dilaudid (TN); Hydromorphone (INN); Palladone (TN); Palladone SR (TN); Morphinan-6-one, 4,5alpha-epoxy-3-hydroxy-17-methyl-(8CI); (-)-(5R)-4,5-Epoxy-3-hydroxy-9alpha-methylmorphinan-6-one; (-)-Hydromorphone; (5alpha)-3-hydroxy-17-methyl-4,5-epoxymorphinan-6-one; 3-hydroxy-17-methyl-4,5alpha-epoxymorphinan-6-one; 4,5alpha-Epoxy-3-hydroxy-17-methyl-6-morphinanone; Hydromorphone prodrug

Indication

Disease Entry	ICD 11	Status	REF
Back pain	ME84.Z	Approved	[1]
Common cold	CA00	Approved	[1]
Cough	MD12	Approved	[1]
Pain	MG30-MG3Z	Approved	[2]
Chronic pain	MG30	Phase 3	[3]

• Therapeutic Class: Analgesics
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 285.34
  Logarithm of the Partition Coefficient (xlogp); 1.8
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 4
• ADMET Property:
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 9 h [4]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
  Bioavailability: The bioavailability of drug is 60% [4]
  Clearance: The sytemic clearance of drug is 1.96 L/min [6]
  Elimination: The elimination of the parent compound represents 7% of the urine elimination and 1% of the fecal elimination [4]
  Half-life: The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [4]
  Metabolism: The drug is metabolized via the hepatic [4]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 1.20158 micromolar/kg/day [7]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.86% [8]
  Vd: The volume of distribution (Vd) of drug is 4 L/kg [4]
  Water Solubility: The ability of drug to dissolve in water is measured as 10 mg/mL [5]
• Chemical Identifiers:
  Formula: C17H19NO3
  IUPAC Name: (4R,4aR,7aR,12bS)-9-hydroxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one
  Canonical SMILES: CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4
  InChI: InChI=1S/C17H19NO3/c1-18-7-6-17-10-3-5-13(20)16(17)21-15-12(19)4-2-9(14(15)17)8-11(10)18/h2,4,10-11,16,19H,3,5-8H2,1H3/t10-,11+,16-,17-/m0/s1
  InChIKey: WVLOADHCBXTIJK-YNHQPCIGSA-N
• Cross-matching ID:
  PubChem CID: 5284570
  ChEBI ID: CHEBI:5790
  CAS Number: 466-99-9
  DrugBank ID: DB00327
  TTD ID: D04JHN
  INTEDE ID: DR0833
  ACDINA ID: D00315
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Opioid receptor delta (OPRD1)	TT27RFC	OPRD_HUMAN	Binder	[9]
Opioid receptor mu (MOP)	TTKWM86	OPRM_HUMAN	Inhibitor	[10]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[11]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[12]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[13]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[14]
UDP-glucuronosyltransferase 2B7 (UGT2B7) Main DME	DEB3CV1	UD2B7_HUMAN	Substrate	[15]
UDP-glucuronosyltransferase 1A3 (UGT1A3)	DEF2WXN	UD13_HUMAN	Substrate	[15]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5-hydroxytryptamine receptor 3A (HTR3A)	OTAIV1AK	5HT3A_HUMAN	Gene/Protein Processing	[16]

Molecular Expression Atlas of This Drug

• The Studied Disease: Back pain
• ICD Disease Classification: ME84.Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Opioid receptor mu (MOP)	DTT	OPRM1	5.94E-01	-0.02	-0.17
Opioid receptor delta (OPRD1)	DTT	OPRD1	5.52E-01	0.03	0.23
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.87E-01	4.98E-02	3.61E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	5.64E-01	2.36E-02	1.75E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	7.83E-01	2.32E-03	1.53E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	6.06E-01	-2.42E-02	-1.64E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Hydromorphone

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Pentazocine	DM1XBHS	Major	Additive hypotensive effects by the combination of Hydromorphone and Pentazocine.	Pain [MG30-MG3Z]	[17]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Hydromorphone and Dextropropoxyphene.	Pain [MG30-MG3Z]	[18]
Butorphanol	DM5KYPJ	Major	Additive CNS depression effects by the combination of Hydromorphone and Butorphanol.	Pain [MG30-MG3Z]	[17]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Hydromorphone and Oxymorphone.	Pain [MG30-MG3Z]	[19]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Hydromorphone and Levorphanol.	Pain [MG30-MG3Z]	[19]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Hydromorphone and Dezocine.	Pain [MG30-MG3Z]	[17]
Flavoxate	DMKV4NL	Moderate	Additive antimotility effects by the combination of Hydromorphone and Flavoxate.	Pain [MG30-MG3Z]	[20]
Nalbuphine	DMOSQGU	Major	Additive hypotensive effects by the combination of Hydromorphone and Nalbuphine.	Pain [MG30-MG3Z]	[17]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Hydromorphone and Buprenorphine.	Pain [MG30-MG3Z]	[17]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Hydromorphone and Hydrocodone.	Pain [MG30-MG3Z]	[19]
Meperidine	DMX4GND	Major	Additive CNS depression effects by the combination of Hydromorphone and Meperidine.	Pain [MG30-MG3Z]	[19]
Oxycodone	DMXLKHV	Major	Additive CNS depression effects by the combination of Hydromorphone and Oxycodone.	Pain [MG30-MG3Z]	[19]

Coadministration of a Drug Treating the Disease Different from Hydromorphone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Hydromorphone and Oliceridine.	Acute pain [MG31]	[19]
Chlorzoxazone	DMCYVDT	Major	Additive CNS depression effects by the combination of Hydromorphone and Chlorzoxazone.	Acute pain [MG31]	[19]
Scopolamine	DMOM8AL	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Scopolamine.	Addictive disorder [6C50-6C5Z]	[21]
Buspirone	DMBS632	Major	Additive CNS depression effects by the combination of Hydromorphone and Buspirone.	Anxiety disorder [6B00-6B0Z]	[19]
Clorazepate	DMC3JST	Major	Additive CNS depression effects by the combination of Hydromorphone and Clorazepate.	Anxiety disorder [6B00-6B0Z]	[22]
Alprazolam	DMC7XDN	Major	Additive CNS depression effects by the combination of Hydromorphone and Alprazolam.	Anxiety disorder [6B00-6B0Z]	[19]
Methylphenobarbital	DMDSWAG	Major	Additive CNS depression effects by the combination of Hydromorphone and Methylphenobarbital.	Anxiety disorder [6B00-6B0Z]	[22]
Hydroxyzine	DMF8Y74	Major	Additive CNS depression effects by the combination of Hydromorphone and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[19]
Halazepam	DMPFWO6	Major	Additive CNS depression effects by the combination of Hydromorphone and Halazepam.	Anxiety disorder [6B00-6B0Z]	[19]
Chlordiazepoxide	DMTN5XI	Major	Additive CNS depression effects by the combination of Hydromorphone and Chlordiazepoxide.	Anxiety disorder [6B00-6B0Z]	[19]
Chlormezanone	DMTWUXR	Major	Additive CNS depression effects by the combination of Hydromorphone and Chlormezanone.	Anxiety disorder [6B00-6B0Z]	[19]
Clobazam - Lundbeck	DMW1OQ0	Major	Additive CNS depression effects by the combination of Hydromorphone and Clobazam - Lundbeck.	Anxiety disorder [6B00-6B0Z]	[19]
Oxazepam	DMXNZM4	Major	Additive CNS depression effects by the combination of Hydromorphone and Oxazepam.	Anxiety disorder [6B00-6B0Z]	[19]
Promazine	DMZAL7W	Major	Additive CNS depression effects by the combination of Hydromorphone and Promazine.	Appearance/behaviour symptom [MB23]	[19]
Desipramine	DMT2FDC	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[23]
Cariprazine	DMJYDVK	Major	Additive CNS depression effects by the combination of Hydromorphone and Cariprazine.	Bipolar disorder [6A60]	[19]
Loperamide	DMOJZQ9	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Loperamide.	Bowel habit change [ME05]	[24]
Secobarbital	DM14RF5	Major	Additive CNS depression effects by the combination of Hydromorphone and Secobarbital.	Chronic insomnia [7A00]	[19]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Hydromorphone and Dihydrocodeine.	Chronic pain [MG30]	[22]
Levomilnacipran	DMV26S8	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Levomilnacipran.	Chronic pain [MG30]	[23]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Olopatadine.	Conjunctiva disorder [9A60]	[25]
Propofol	DMB4OLE	Moderate	Additive cardiorespiratory depression effects by the combination of Hydromorphone and Propofol.	Corneal disease [9A76-9A78]	[26]
Methadone	DMTW6IU	Major	Additive CNS depression effects by the combination of Hydromorphone and Methadone.	Cough [MD12]	[19]
Dextromethorphan	DMUDJZM	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Dextromethorphan.	Cough [MD12]	[23]
Ethanol	DMDRQZU	Major	Additive CNS depression effects by the combination of Hydromorphone and Ethanol.	Cystitis [GC00]	[27]
Sertraline	DM0FB1J	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Sertraline.	Depression [6A70-6A7Z]	[23]
Trimipramine	DM1SC8M	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Trimipramine.	Depression [6A70-6A7Z]	[23]
Cyclobenzaprine	DM1YBRM	Major	Additive CNS depression effects by the combination of Hydromorphone and Cyclobenzaprine.	Depression [6A70-6A7Z]	[19]
Imipramine	DM2NUH3	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Imipramine.	Depression [6A70-6A7Z]	[23]
Fluoxetine	DM3PD2C	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Fluoxetine.	Depression [6A70-6A7Z]	[23]
Nortriptyline	DM4KDYJ	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Nortriptyline.	Depression [6A70-6A7Z]	[23]
Vilazodone	DM4LECQ	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Vilazodone.	Depression [6A70-6A7Z]	[23]
Nefazodone	DM4ZS8M	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Nefazodone.	Depression [6A70-6A7Z]	[23]
Paroxetine	DM5PVQE	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Paroxetine.	Depression [6A70-6A7Z]	[23]
Vortioxetine	DM6F1PU	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Vortioxetine.	Depression [6A70-6A7Z]	[23]
Duloxetine	DM9BI7M	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Duloxetine.	Depression [6A70-6A7Z]	[23]
Milnacipran	DMBFE74	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Milnacipran.	Depression [6A70-6A7Z]	[23]
Desvenlafaxine	DMHD4PE	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Desvenlafaxine.	Depression [6A70-6A7Z]	[23]
OPC-34712	DMHG57U	Major	Additive CNS depression effects by the combination of Hydromorphone and OPC-34712.	Depression [6A70-6A7Z]	[19]
Clomipramine	DMINRKW	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Clomipramine.	Depression [6A70-6A7Z]	[23]
Trazodone	DMK1GBJ	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Trazodone.	Depression [6A70-6A7Z]	[23]
Amoxapine	DMKITQE	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Amoxapine.	Depression [6A70-6A7Z]	[23]
Mirtazapine	DML53ZJ	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Mirtazapine.	Depression [6A70-6A7Z]	[23]
Protriptyline	DMNHTZI	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Protriptyline.	Depression [6A70-6A7Z]	[23]
Doxepin	DMPI98T	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Doxepin.	Depression [6A70-6A7Z]	[23]
Maprotiline	DMPWB7T	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Maprotiline.	Depression [6A70-6A7Z]	[23]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Esketamine.	Depression [6A70-6A7Z]	[28]
Hyoscyamine	DM804UR	Moderate	Additive antimotility effects by the combination of Hydromorphone and Hyoscyamine.	Digestive system disease [DE2Z]	[21]
Mepenzolate	DM8YU2F	Moderate	Additive antimotility effects by the combination of Hydromorphone and Mepenzolate.	Digestive system disease [DE2Z]	[21]
5-hydroxy-L-tryptophan	DMDWZGJ	Moderate	Additive CNS depression effects by the combination of Hydromorphone and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[23]
Oxybutynine	DMJPBAX	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Oxybutynine.	Discovery agent [N.A.]	[21]
Heroin diacetylmorphine	DMDBWHY	Major	Additive CNS depression effects by the combination of Hydromorphone and Heroin diacetylmorphine.	Dissociative neurological symptom disorder [6B60]	[22]
Trihexyphenidyl	DMB19L8	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Trihexyphenidyl.	Dystonic disorder [8A02]	[29]
Fenfluramine	DM0762O	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Fenfluramine.	Epilepsy/seizure [8A61-8A6Z]	[23]
Diazepam	DM08E9O	Major	Additive CNS depression effects by the combination of Hydromorphone and Diazepam.	Epilepsy/seizure [8A61-8A6Z]	[19]
Primidone	DM0WX6I	Major	Additive CNS depression effects by the combination of Hydromorphone and Primidone.	Epilepsy/seizure [8A61-8A6Z]	[19]
Gabapentin	DM6T924	Major	Additive CNS depression effects by the combination of Hydromorphone and Gabapentin.	Epilepsy/seizure [8A61-8A6Z]	[30]
Clonazepam	DMTO13J	Major	Additive CNS depression effects by the combination of Hydromorphone and Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[19]
Phenobarbital	DMXZOCG	Major	Additive CNS depression effects by the combination of Hydromorphone and Phenobarbital.	Epilepsy/seizure [8A61-8A6Z]	[19]
Dantrolene	DM1D8XY	Major	Additive CNS depression effects by the combination of Hydromorphone and Dantrolene.	Fever [MG26]	[19]
Solifenacin	DMG592Q	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Solifenacin.	Functional bladder disorder [GC50]	[21]
Tolterodine	DMSHPW8	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Tolterodine.	Functional bladder disorder [GC50]	[21]
Darifenacin	DMWXLYZ	Moderate	Additive antimotility effects by the combination of Hydromorphone and Darifenacin.	Functional bladder disorder [GC50]	[20]
Propantheline	DM2EN6G	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Propantheline.	Gastric ulcer [DA60]	[21]
Brimonidine	DMQLT4N	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Brimonidine.	Glaucoma [9C61]	[31]
Belladonna	DM2RBWK	Moderate	Additive antimotility effects by the combination of Hydromorphone and Belladonna.	Infectious gastroenteritis/colitis [1A40]	[20]
Suvorexant	DM0E6S3	Major	Additive CNS depression effects by the combination of Hydromorphone and Suvorexant.	Insomnia [7A00-7A0Z]	[19]
Amobarbital	DM0GQ8N	Major	Additive CNS depression effects by the combination of Hydromorphone and Amobarbital.	Insomnia [7A00-7A0Z]	[19]
Ramelteon	DM7IW9J	Major	Additive CNS depression effects by the combination of Hydromorphone and Ramelteon.	Insomnia [7A00-7A0Z]	[19]
Eszopiclone	DM8RZ9H	Major	Additive CNS depression effects by the combination of Hydromorphone and Eszopiclone.	Insomnia [7A00-7A0Z]	[19]
Flurazepam	DMAL4G0	Major	Additive CNS depression effects by the combination of Hydromorphone and Flurazepam.	Insomnia [7A00-7A0Z]	[19]
Triazolam	DMETYK5	Major	Additive CNS depression effects by the combination of Hydromorphone and Triazolam.	Insomnia [7A00-7A0Z]	[19]
Zaleplon	DMGFWSM	Major	Additive CNS depression effects by the combination of Hydromorphone and Zaleplon.	Insomnia [7A00-7A0Z]	[19]
Propiomazine	DMKY8V1	Major	Additive CNS depression effects by the combination of Hydromorphone and Propiomazine.	Insomnia [7A00-7A0Z]	[19]
Tasimelteon	DMLOQ1V	Major	Additive CNS depression effects by the combination of Hydromorphone and Tasimelteon.	Insomnia [7A00-7A0Z]	[19]
Paraldehyde	DMOC1BX	Major	Additive CNS depression effects by the combination of Hydromorphone and Paraldehyde.	Insomnia [7A00-7A0Z]	[19]
ITI-007	DMUQ1DO	Major	Additive CNS depression effects by the combination of Hydromorphone and ITI-007.	Insomnia [7A00-7A0Z]	[19]
Zolpidem	DMWOSKJ	Major	Additive CNS depression effects by the combination of Hydromorphone and Zolpidem.	Insomnia [7A00-7A0Z]	[19]
Quazepam	DMY4D87	Major	Additive CNS depression effects by the combination of Hydromorphone and Quazepam.	Insomnia [7A00-7A0Z]	[19]
Estazolam	DMZGXUM	Major	Additive CNS depression effects by the combination of Hydromorphone and Estazolam.	Insomnia [7A00-7A0Z]	[19]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Hydromorphone and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[32]
Clidinium	DMUMQZ0	Moderate	Additive antimotility effects by the combination of Hydromorphone and Clidinium.	Irritable bowel syndrome [DD91]	[20]
Dicyclomine	DMZSDGX	Moderate	Additive antimotility effects by the combination of Hydromorphone and Dicyclomine.	Irritable bowel syndrome [DD91]	[20]
Remimazolam	DMLVSYX	Major	Additive CNS depression effects by the combination of Hydromorphone and Remimazolam.	Labour/delivery anaesthesia complication [JB0C]	[19]
Meprobamate	DMHM93Y	Major	Additive CNS depression effects by the combination of Hydromorphone and Meprobamate.	Malaria [1F40-1F45]	[19]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[33]
Almogran	DM7I64Z	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Almogran.	Migraine [8A80]	[23]
Frovatriptan	DM7RE8P	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Frovatriptan.	Migraine [8A80]	[23]
Rizatriptan	DMDJMA3	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Rizatriptan.	Migraine [8A80]	[23]
Naratriptan	DMO50U2	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Naratriptan.	Migraine [8A80]	[23]
Sumatriptan	DMVYXR8	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Sumatriptan.	Migraine [8A80]	[23]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Lasmiditan.	Migraine [8A80]	[34]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Flibanserin.	Mood disorder [6A60-6E23]	[35]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Thalidomide.	Multiple myeloma [2A83]	[36]
Carisoprodol	DMWR1JC	Major	Additive CNS depression effects by the combination of Hydromorphone and Carisoprodol.	Musculoskeletal disorder [FA00-FC0Z]	[19]
Prasugrel	DM7MT6E	Moderate	Altered absorption of Hydromorphone due to GI dynamics variation caused by Prasugrel.	Myocardial infarction [BA41-BA43]	[37]
Droperidol	DM0DXA8	Major	Additive cardiorespiratory depression effects by the combination of Hydromorphone and Droperidol.	Nausea/vomiting [MD90]	[38]
Palonosetron	DMBHMOX	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Palonosetron.	Nausea/vomiting [MD90]	[23]
Metoclopramide	DMFA5MY	Moderate	Additive antimotility effects by the combination of Hydromorphone and Metoclopramide.	Nausea/vomiting [MD90]	[39]
Granisetron	DMIUW25	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Granisetron.	Nausea/vomiting [MD90]	[23]
Dolasetron	DMMG26Z	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Dolasetron.	Nausea/vomiting [MD90]	[23]
Ondansetron	DMOTQ1I	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Ondansetron.	Nausea/vomiting [MD90]	[23]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Hydromorphone and Bupropion.	Nicotine use disorder [6C4A]	[40]
Sibutramine	DMFJTDI	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Sibutramine.	Obesity [5B80-5B81]	[23]
Dexfenfluramine	DMJ7YDS	Moderate	Additive serotonergic effects by the combination of Hydromorphone and Dexfenfluramine.	Obesity [5B80-5B81]	[23]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Apraclonidine.	Optic nerve disorder [9C40]	[31]
Biperiden	DME78OA	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Biperiden.	Parkinsonism [8A00]	[29]
Procyclidine	DMHFJDT	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Procyclidine.	Parkinsonism [8A00]	[29]
Pimavanserin	DMR7IVC	Major	Additive CNS depression effects by the combination of Hydromorphone and Pimavanserin.	Parkinsonism [8A00]	[19]
Orphenadrine	DMW542E	Major	Additive CNS depression effects by the combination of Hydromorphone and Orphenadrine.	Parkinsonism [8A00]	[19]
Lindane	DMB8CNL	Moderate	Increased risk of lowers seizure threshold by the combination of Hydromorphone and Lindane.	Pediculosis [1G00]	[41]
Methylscopolamine	DM5VWOB	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Methylscopolamine.	Peptic ulcer [DA61]	[21]
Fluphenazine	DMIT8LX	Major	Additive CNS depression effects by the combination of Hydromorphone and Fluphenazine.	Psychotic disorder [6A20-6A25]	[42]
Triflupromazine	DMKFQJP	Major	Additive CNS depression effects by the combination of Hydromorphone and Triflupromazine.	Psychotic disorder [6A20-6A25]	[19]
Quetiapine	DM1N62C	Major	Additive CNS depression effects by the combination of Hydromorphone and Quetiapine.	Schizophrenia [6A20]	[43]
Mesoridazine	DM2ZGAN	Major	Additive CNS depression effects by the combination of Hydromorphone and Mesoridazine.	Schizophrenia [6A20]	[43]
Thioridazine	DM35M8J	Major	Additive CNS depression effects by the combination of Hydromorphone and Thioridazine.	Schizophrenia [6A20]	[19]
Aripiprazole	DM3NUMH	Major	Additive CNS depression effects by the combination of Hydromorphone and Aripiprazole.	Schizophrenia [6A20]	[19]
Iloperidone	DM6AUFY	Major	Additive CNS depression effects by the combination of Hydromorphone and Iloperidone.	Schizophrenia [6A20]	[19]
Paliperidone	DM7NPJS	Major	Additive CNS depression effects by the combination of Hydromorphone and Paliperidone.	Schizophrenia [6A20]	[19]
Loxapine	DM8AI9U	Major	Additive CNS depression effects by the combination of Hydromorphone and Loxapine.	Schizophrenia [6A20]	[43]
Haloperidol	DM96SE0	Major	Additive CNS depression effects by the combination of Hydromorphone and Haloperidol.	Schizophrenia [6A20]	[19]
Perphenazine	DMA4MRX	Major	Additive CNS depression effects by the combination of Hydromorphone and Perphenazine.	Schizophrenia [6A20]	[19]
Molindone	DMAH70G	Major	Additive CNS depression effects by the combination of Hydromorphone and Molindone.	Schizophrenia [6A20]	[19]
Chlorpromazine	DMBGZI3	Major	Additive CNS depression effects by the combination of Hydromorphone and Chlorpromazine.	Schizophrenia [6A20]	[42]
Thiothixene	DMDINC4	Major	Additive CNS depression effects by the combination of Hydromorphone and Thiothixene.	Schizophrenia [6A20]	[43]
Clozapine	DMFC71L	Major	Additive CNS depression effects by the combination of Hydromorphone and Clozapine.	Schizophrenia [6A20]	[42]
Trifluoperazine	DMKBYWI	Major	Additive CNS depression effects by the combination of Hydromorphone and Trifluoperazine.	Schizophrenia [6A20]	[19]
Risperidone	DMN6DXL	Major	Additive CNS depression effects by the combination of Hydromorphone and Risperidone.	Schizophrenia [6A20]	[19]
Olanzapine	DMPFN6Y	Major	Additive CNS depression effects by the combination of Hydromorphone and Olanzapine.	Schizophrenia [6A20]	[43]
Asenapine	DMSQZE2	Major	Additive CNS depression effects by the combination of Hydromorphone and Asenapine.	Schizophrenia [6A20]	[19]
Pimozide	DMW83TP	Major	Additive CNS depression effects by the combination of Hydromorphone and Pimozide.	Schizophrenia [6A20]	[19]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Hydromorphone and Fentanyl.	Sensation disturbance [MB40]	[19]
Brilinta	DMBR01X	Moderate	Altered absorption of Hydromorphone due to GI dynamics variation caused by Brilinta.	Thrombosis [DB61-GB90]	[37]
Clopidogrel	DMOL54H	Moderate	Altered absorption of Hydromorphone due to GI dynamics variation caused by Clopidogrel.	Thrombosis [DB61-GB90]	[37]
Tizanidine	DMR2IQ4	Major	Additive CNS depression effects by the combination of Hydromorphone and Tizanidine.	Tonus and reflex abnormality [MB47]	[19]
Atropine	DMEN6X7	Moderate	Additive antimotility effects by the combination of Hydromorphone and Atropine.	Unspecific substance harmful effect [NE6Z]	[20]
Cetirizine	DMOMP9U	Moderate	Additive CNS depression effects by the combination of Hydromorphone and Cetirizine.	Vasomotor/allergic rhinitis [CA08]	[44]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Butylated hydroxytoluene	E00336	31404	Antioxidant
D&C red no. 30	E00456	3000709	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS	E00309	24671	Colorant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferric oxide black	E00522	16211978	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium chloride	E00077	5234	Diluent; Tonicity agent
Sodium metabisulfite	E00444	656671	Antimicrobial preservative; Antioxidant
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Hydromorphone 2 mg tablet	2 mg	Oral Tablet	Oral
Hydromorphone 4 mg tablet	4 mg	Oral Tablet	Oral
Hydromorphone 8 mg tablet	8 mg	Oral Tablet	Oral
Hydromorphone 24 mg capsule	24 mg	24 HR Extended Release Capsule	Oral
Hydromorphone 16 mg tablet	16 mg	24 HR Extended Release Oral Tablet	Oral
Hydromorphone 12 mg tablet	12 mg	24 HR Extended Release Oral Tablet	Oral
Hydromorphone 8 mg tablet	8 mg	24 HR Extended Release Oral Tablet	Oral
Hydromorphone 32 mg tablet	32 mg	24 HR Extended Release Oral Tablet	Oral
Hydromorphone 12 mg capsule	12 mg	24 HR Extended Release Capsule	Oral
Hydromorphone 16 mg capsule	16 mg	24 HR Extended Release Capsule	Oral
Hydromorphone 32 mg capsule	32 mg	24 HR Extended Release Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] Hydromorphone FDA Label
• [2] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Hydromorphone .
• [5] BDDCS applied to over 900 drugs
• [6] Perlman R, Giladi H, Brecht K, Ware MA, Hebert TE, Joseph L, Shir Y: Intradialytic clearance of opioids: methadone versus hydromorphone. Pain. 2013 Dec;154(12):2794-800. doi: 10.1016/j.pain.2013.08.015. Epub 2013 Aug 20.
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [9] Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone]. J Med Chem. 2004 Mar 11;47(6):1400-12.
• [10] Clinical pipeline report, company report or official report of signaturerx.
• [11] Capillary electrophoresis contributions to the hydromorphone metabolism in man. Electrophoresis. 2006 Jun;27(12):2444-57.
• [12] Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J Pharmacol Exp Ther. 1997 Mar;280(3):1374-82.
• [13] Role of individual human cytochrome P450 enzymes in the in vitro metabolism of hydromorphone. Xenobiotica. 2004 Apr;34(4):335-44.
• [14] Is maternal opioid use hazardous to breast-fed infants? Clin Toxicol (Phila). 2012 Jan;50(1):1-14.
• [15] Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
• [16] The effects of fentanyl-like opioids and hydromorphone on human 5-HT3A receptors. Anesth Analg. 2008 Jul;107(1):107-12. doi: 10.1213/ane.0b013e31817342c2.
• [17] Product Information. Buprenex (buprenorphine). Reckitt and Colman Pharmaceutical, Richmond, VA.
• [18] Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7. [PMID: 2858217]
• [19] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [20] Product Information. Apadaz (acetaminophen-benzhydrocodone). KemPharm, Inc, Coralville, IA.
• [21] Product Information. Levorphanol Tartrate (levorphanol). Sentynl Therapeutics, Solana Beach, CA.
• [22] US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
• [23] Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
• [24] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [26] Gill SS, Wright EM, Reilly CS "Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study." Br J Anaesth 65 (1990): 760-5. [PMID: 2265045]
• [27] Levine B, Saady J, Fierro M, Valentour J "A hydromorphone and ethanol fatality." J Forensic Sci 29 (1984): 655-9. [PMID: 6202821]
• [28] Cerner Multum, Inc. "Australian Product Information.".
• [29] Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
• [30] Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G "Gabapentin enhances the analgesic effect of morphine in healthy volunteers." Anesth Analg 91 (2000): 185-91. [PMID: 10866910]
• [31] Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
• [32] Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
• [33] Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
• [34] Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
• [35] Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
• [36] Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
• [37] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [38] Canadian Pharmacists Association.
• [39] Manara AR, Shelly MP, Quinn K, Park GR "The effect of metoclopramide on the absorption of oral controlled release morphine." Br J Clin Pharmacol 25 (1988): 518-21. [PMID: 3382595]
• [40] Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
• [41] Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
• [42] Cerner Multum, Inc. "Canadian Product Information.".
• [43] Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
• [44] Product Information. Zyrtec (cetirizine). Pfizer US Pharmaceuticals, New York, NY.